explore -WSS

explore

author：fashion 2025-10-03 00:04:40 - browse：8

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： FDA moves to stop vape shops from selling Elf Bar, Esco Bars

focus

WSS

AI can’t replace a physician’s gut feeling

Novo Nordisk to expand supply of Wegovy for U.S. patients

Listen: Wegovy in the brain & pivotal Alzheimer's data

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

In early work, researchers turn to CRISPR to treat Alzheimer's

Covid misinformation case heads to Supreme Court

focus

explore

leisure time

Cancer drug shortages should be causing more outrage

Covid misinformation case heads to Supreme Court

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

How to save PrEP access — and even expand it

Cosmetics set for new safety regulation. Why the industry is on board

Guidelines to prevent youth baseball injuries need more muscle

Medicare drug price negotiation’s day in court

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How dance can help nurses traumatized by Covid

Wikipedia

Cosmetics set for new safety regulation. Why the industry is on board

SAMSHA loosens regulations on methadone treatment centers

Listen: Wegovy in the brain & pivotal Alzheimer's data

Juul spent big to court Black leaders to promote its e

SAMSHA loosens regulations on methadone treatment centers

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

focus

focus

leisure time

hotspot